PAN to provide co-payment assistance for medications to underinsured patients through five new funds

NewsGuard 100/100 Score

Patient Access Network (PAN) Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients.  The other new funds will provide access to medications for patients with hepatitis B or C, non-kidney solid organ transplants, cytomegalovirus (or CMV), and acromegaly.

These new funds are an expansion of PAN's 21 existing cancer and chronic disease funds, which cover conditions such as rheumatoid arthritis, breast cancer, and colorectal cancer. PAN provides grants of $1,500-$10,000 per year to qualified patients to help pay for medications for these diseases.  In 2009 PAN helped over 18,821 patients access their medications.

PAN President, Julie Reynes, says these new disease areas will allow the organization to help more patients than ever in 2010. "Every day we hear from patients tell us our assistance saved their lives.   We are pleased to be able to finally help with the largest area of unmet need--prostate cancer."

Demand for co-payment assistance has risen dramatically in the past year with most co-payment assistance organizations reporting at least a 20% increase in demand.  PAN is optimistic that these new funds will help meet this rising demand.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer